The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Next Generation Cancer Diagnostics-Global Market Insights and Sales Trends 2024
Synopsis
The global Next Generation Cancer Diagnostics market size is expected to reach US$ 20950 million by 2029, growing at a CAGR of 18.5% from 2023 to 2029. The market is mainly driven by the significant applications of Next Generation Cancer Diagnostics in various end use industries. The expanding demands from the Hospitals, Clinics and Others,, are propelling Next Generation Cancer Diagnostics market. Next Generation Sequencing, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the qPCR & Multiplexing segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Next Generation Cancer Diagnostics market, driven by demand from China, the second largest economy with some signs of stabilising, the Next Generation Cancer Diagnostics market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Next Generation Cancer Diagnostics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Next Generation Cancer Diagnostics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Next Generation Cancer Diagnostics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Next Generation Cancer Diagnostics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Next Generation Cancer Diagnostics covered in this report include Cepheid, Koninklijke Philips N.V, F. Hoffmann-La Roche Ltd, Qiagen, Novartis AG, Abbott, Thermo Fisher Scientific, Opko Health and Myriad Genetics, etc.
The global Next Generation Cancer Diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Cepheid
Koninklijke Philips N.V
F. Hoffmann-La Roche Ltd
Qiagen
Novartis AG
Abbott
Thermo Fisher Scientific
Opko Health
Myriad Genetics
Agilent Technologies
GE Healthcare
PerkinElmer
Genomic Health
Illumina
Hologic
Almac Group
Janssen Global Services
Sysmex Corporation
Global Next Generation Cancer Diagnostics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Next Generation Cancer Diagnostics market, Segment by Type:
Next Generation Sequencing
qPCR & Multiplexing
DNA Microarrays
Others
Global Next Generation Cancer Diagnostics market, by Application
Hospitals
Clinics
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Next Generation Cancer Diagnostics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
The global Next Generation Cancer Diagnostics market size is expected to reach US$ 20950 million by 2029, growing at a CAGR of 18.5% from 2023 to 2029. The market is mainly driven by the significant applications of Next Generation Cancer Diagnostics in various end use industries. The expanding demands from the Hospitals, Clinics and Others,, are propelling Next Generation Cancer Diagnostics market. Next Generation Sequencing, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the qPCR & Multiplexing segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for Next Generation Cancer Diagnostics market, driven by demand from China, the second largest economy with some signs of stabilising, the Next Generation Cancer Diagnostics market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Next Generation Cancer Diagnostics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Next Generation Cancer Diagnostics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Next Generation Cancer Diagnostics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Next Generation Cancer Diagnostics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Next Generation Cancer Diagnostics covered in this report include Cepheid, Koninklijke Philips N.V, F. Hoffmann-La Roche Ltd, Qiagen, Novartis AG, Abbott, Thermo Fisher Scientific, Opko Health and Myriad Genetics, etc.
The global Next Generation Cancer Diagnostics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Cepheid
Koninklijke Philips N.V
F. Hoffmann-La Roche Ltd
Qiagen
Novartis AG
Abbott
Thermo Fisher Scientific
Opko Health
Myriad Genetics
Agilent Technologies
GE Healthcare
PerkinElmer
Genomic Health
Illumina
Hologic
Almac Group
Janssen Global Services
Sysmex Corporation
Global Next Generation Cancer Diagnostics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Next Generation Cancer Diagnostics market, Segment by Type:
Next Generation Sequencing
qPCR & Multiplexing
DNA Microarrays
Others
Global Next Generation Cancer Diagnostics market, by Application
Hospitals
Clinics
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Next Generation Cancer Diagnostics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Next Generation Cancer Diagnostics
1.1 Next Generation Cancer Diagnostics Market Overview
1.1.1 Next Generation Cancer Diagnostics Product Scope
1.1.2 Next Generation Cancer Diagnostics Market Status and Outlook
1.2 Global Next Generation Cancer Diagnostics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Next Generation Cancer Diagnostics Market Size by Region (2018-2029)
1.4 Global Next Generation Cancer Diagnostics Historic Market Size by Region (2018-2023)
1.5 Global Next Generation Cancer Diagnostics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Next Generation Cancer Diagnostics Market Size (2018-2029)
1.6.1 North America Next Generation Cancer Diagnostics Market Size (2018-2029)
1.6.2 Europe Next Generation Cancer Diagnostics Market Size (2018-2029)
1.6.3 Asia-Pacific Next Generation Cancer Diagnostics Market Size (2018-2029)
1.6.4 Latin America Next Generation Cancer Diagnostics Market Size (2018-2029)
1.6.5 Middle East & Africa Next Generation Cancer Diagnostics Market Size (2018-2029)
2 Next Generation Cancer Diagnostics Market by Type
2.1 Introduction
2.1.1 Next Generation Sequencing
2.1.2 qPCR & Multiplexing
2.1.3 DNA Microarrays
2.1.4 Others
2.2 Global Next Generation Cancer Diagnostics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Next Generation Cancer Diagnostics Historic Market Size by Type (2018-2023)
2.2.2 Global Next Generation Cancer Diagnostics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Next Generation Cancer Diagnostics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Next Generation Cancer Diagnostics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Next Generation Cancer Diagnostics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Next Generation Cancer Diagnostics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Next Generation Cancer Diagnostics Revenue Breakdown by Type (2018-2029)
3 Next Generation Cancer Diagnostics Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Clinics
3.1.3 Others
3.2 Global Next Generation Cancer Diagnostics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Next Generation Cancer Diagnostics Historic Market Size by Application (2018-2023)
3.2.2 Global Next Generation Cancer Diagnostics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Next Generation Cancer Diagnostics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Next Generation Cancer Diagnostics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Next Generation Cancer Diagnostics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Next Generation Cancer Diagnostics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Next Generation Cancer Diagnostics Revenue Breakdown by Application (2018-2029)
4 Next Generation Cancer Diagnostics Competition Analysis by Players
4.1 Global Next Generation Cancer Diagnostics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Next Generation Cancer Diagnostics as of 2022)
4.3 Date of Key Players Enter into Next Generation Cancer Diagnostics Market
4.4 Global Top Players Next Generation Cancer Diagnostics Headquarters and Area Served
4.5 Key Players Next Generation Cancer Diagnostics Product Solution and Service
4.6 Competitive Status
4.6.1 Next Generation Cancer Diagnostics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Cepheid
5.1.1 Cepheid Profile
5.1.2 Cepheid Main Business
5.1.3 Cepheid Next Generation Cancer Diagnostics Products, Services and Solutions
5.1.4 Cepheid Next Generation Cancer Diagnostics Revenue (US$ Million) & (2018-2023)
5.1.5 Cepheid Recent Developments
5.2 Koninklijke Philips N.V
5.2.1 Koninklijke Philips N.V Profile
5.2.2 Koninklijke Philips N.V Main Business
5.2.3 Koninklijke Philips N.V Next Generation Cancer Diagnostics Products, Services and Solutions
5.2.4 Koninklijke Philips N.V Next Generation Cancer Diagnostics Revenue (US$ Million) & (2018-2023)
5.2.5 Koninklijke Philips N.V Recent Developments
5.3 F. Hoffmann-La Roche Ltd
5.3.1 F. Hoffmann-La Roche Ltd Profile
5.3.2 F. Hoffmann-La Roche Ltd Main Business
5.3.3 F. Hoffmann-La Roche Ltd Next Generation Cancer Diagnostics Products, Services and Solutions
5.3.4 F. Hoffmann-La Roche Ltd Next Generation Cancer Diagnostics Revenue (US$ Million) & (2018-2023)
5.3.5 Qiagen Recent Developments
5.4 Qiagen
5.4.1 Qiagen Profile
5.4.2 Qiagen Main Business
5.4.3 Qiagen Next Generation Cancer Diagnostics Products, Services and Solutions
5.4.4 Qiagen Next Generation Cancer Diagnostics Revenue (US$ Million) & (2018-2023)
5.4.5 Qiagen Recent Developments
5.5 Novartis AG
5.5.1 Novartis AG Profile
5.5.2 Novartis AG Main Business
5.5.3 Novartis AG Next Generation Cancer Diagnostics Products, Services and Solutions
5.5.4 Novartis AG Next Generation Cancer Diagnostics Revenue (US$ Million) & (2018-2023)
5.5.5 Novartis AG Recent Developments
5.6 Abbott
5.6.1 Abbott Profile
5.6.2 Abbott Main Business
5.6.3 Abbott Next Generation Cancer Diagnostics Products, Services and Solutions
5.6.4 Abbott Next Generation Cancer Diagnostics Revenue (US$ Million) & (2018-2023)
5.6.5 Abbott Recent Developments
5.7 Thermo Fisher Scientific
5.7.1 Thermo Fisher Scientific Profile
5.7.2 Thermo Fisher Scientific Main Business
5.7.3 Thermo Fisher Scientific Next Generation Cancer Diagnostics Products, Services and Solutions
5.7.4 Thermo Fisher Scientific Next Generation Cancer Diagnostics Revenue (US$ Million) & (2018-2023)
5.7.5 Thermo Fisher Scientific Recent Developments
5.8 Opko Health
5.8.1 Opko Health Profile
5.8.2 Opko Health Main Business
5.8.3 Opko Health Next Generation Cancer Diagnostics Products, Services and Solutions
5.8.4 Opko Health Next Generation Cancer Diagnostics Revenue (US$ Million) & (2018-2023)
5.8.5 Opko Health Recent Developments
5.9 Myriad Genetics
5.9.1 Myriad Genetics Profile
5.9.2 Myriad Genetics Main Business
5.9.3 Myriad Genetics Next Generation Cancer Diagnostics Products, Services and Solutions
5.9.4 Myriad Genetics Next Generation Cancer Diagnostics Revenue (US$ Million) & (2018-2023)
5.9.5 Myriad Genetics Recent Developments
5.10 Agilent Technologies
5.10.1 Agilent Technologies Profile
5.10.2 Agilent Technologies Main Business
5.10.3 Agilent Technologies Next Generation Cancer Diagnostics Products, Services and Solutions
5.10.4 Agilent Technologies Next Generation Cancer Diagnostics Revenue (US$ Million) & (2018-2023)
5.10.5 Agilent Technologies Recent Developments
5.11 GE Healthcare
5.11.1 GE Healthcare Profile
5.11.2 GE Healthcare Main Business
5.11.3 GE Healthcare Next Generation Cancer Diagnostics Products, Services and Solutions
5.11.4 GE Healthcare Next Generation Cancer Diagnostics Revenue (US$ Million) & (2018-2023)
5.11.5 GE Healthcare Recent Developments
5.12 PerkinElmer
5.12.1 PerkinElmer Profile
5.12.2 PerkinElmer Main Business
5.12.3 PerkinElmer Next Generation Cancer Diagnostics Products, Services and Solutions
5.12.4 PerkinElmer Next Generation Cancer Diagnostics Revenue (US$ Million) & (2018-2023)
5.12.5 PerkinElmer Recent Developments
5.13 Genomic Health
5.13.1 Genomic Health Profile
5.13.2 Genomic Health Main Business
5.13.3 Genomic Health Next Generation Cancer Diagnostics Products, Services and Solutions
5.13.4 Genomic Health Next Generation Cancer Diagnostics Revenue (US$ Million) & (2018-2023)
5.13.5 Genomic Health Recent Developments
5.14 Illumina
5.14.1 Illumina Profile
5.14.2 Illumina Main Business
5.14.3 Illumina Next Generation Cancer Diagnostics Products, Services and Solutions
5.14.4 Illumina Next Generation Cancer Diagnostics Revenue (US$ Million) & (2018-2023)
5.14.5 Illumina Recent Developments
5.15 Hologic
5.15.1 Hologic Profile
5.15.2 Hologic Main Business
5.15.3 Hologic Next Generation Cancer Diagnostics Products, Services and Solutions
5.15.4 Hologic Next Generation Cancer Diagnostics Revenue (US$ Million) & (2018-2023)
5.15.5 Hologic Recent Developments
5.16 Almac Group
5.16.1 Almac Group Profile
5.16.2 Almac Group Main Business
5.16.3 Almac Group Next Generation Cancer Diagnostics Products, Services and Solutions
5.16.4 Almac Group Next Generation Cancer Diagnostics Revenue (US$ Million) & (2018-2023)
5.16.5 Almac Group Recent Developments
5.17 Janssen Global Services
5.17.1 Janssen Global Services Profile
5.17.2 Janssen Global Services Main Business
5.17.3 Janssen Global Services Next Generation Cancer Diagnostics Products, Services and Solutions
5.17.4 Janssen Global Services Next Generation Cancer Diagnostics Revenue (US$ Million) & (2018-2023)
5.17.5 Janssen Global Services Recent Developments
5.18 Sysmex Corporation
5.18.1 Sysmex Corporation Profile
5.18.2 Sysmex Corporation Main Business
5.18.3 Sysmex Corporation Next Generation Cancer Diagnostics Products, Services and Solutions
5.18.4 Sysmex Corporation Next Generation Cancer Diagnostics Revenue (US$ Million) & (2018-2023)
5.18.5 Sysmex Corporation Recent Developments
6 North America
6.1 North America Next Generation Cancer Diagnostics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Next Generation Cancer Diagnostics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Next Generation Cancer Diagnostics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Next Generation Cancer Diagnostics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Next Generation Cancer Diagnostics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Next Generation Cancer Diagnostics Market Dynamics
11.1 Next Generation Cancer Diagnostics Industry Trends
11.2 Next Generation Cancer Diagnostics Market Drivers
11.3 Next Generation Cancer Diagnostics Market Challenges
11.4 Next Generation Cancer Diagnostics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
